https://www.selleckchem.com/
33% (95% CI 37.87-68.34%), 80.47% (95% CI 72.53-86.94%), and 88.24% (95% CI 82.05-92.88%) in panel 1 (days 0-13), panel 2 (days 14-2 and panel 3 (days 21-27), respectively. Higher sensitivity was achieved in symptomatic individuals and reached 92.14% (95% CI 86.38-96.01%) for panel 3. Our test, with a shorter runtime, showed higher sensitivity than parallelly tested commercial ELISAs for SARS-CoV-2-IgG, i.e., Euroimmun and Zydus, even when equivocal results in the commercial ELISAs were considered positive. None of the tests, which are using different ant
Curtir
Comentario
Compartilhar
